オプションチェーンは、Coeptis Therapeuticsの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Coeptis Therapeuticsの市場センチメントを評価します。.

Coeptis Therapeutics (NASDAQ:COEP) 株価情報, オプションチェーン

Coeptis Therapeutics

Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.

Coeptis Therapeutics Holdings, Inc. - Common Stock

Coeptis Therapeutics Holdings Inc

Coeptis Therapeutics Holdings, Inc. - Warrants

Loop Capital analyst Rob Sanderson maintains Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) with a Buy and lowers the price target from $900 to $695.

News

Price Target

Analyst Ratings

Loop Capital Maintains Buy on Meta Platforms, Lowers Price Target to $695

<ul>
<li>TSLA</li>
<li>NVDA</li>
<li>GLD</li>
<li>BULL</li>
<li>WOLF</li>
<li>AAPL</li>
<li>$BTC</li>
<li>HOOD</li>
<li>GOOGL</li>
<li>MAGA</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

Trading Ideas

$BTC

AAPL

BULL

GOOGL

HOOD

MAGA

NVDA

TSLA

WOLF

Top 10 Trending Stocks On WallStreetBets As Of April 28, 2025 (Via Swaggy Stocks)

The Safari Collection is a world-renowned luxury safari company and owner of the Giraffe Manor
This is another leading safari company in Africa that has placed an order with Tembo
The first order was from Asilia Africa announced in February 2025
Tembo's solutions selected to drive sustainable safari experiences across Kenya
LONDON, April 28, 2025 (GLOBE NEWSWIRE) -- VivoPower International PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVPR#NASDAQ">VVPR</a>, the "Company"))) is pleased to announce that its wholly-owned subsidiary, Tembo e-LV, has secured an inaugural order for its EV conversion kits from The Safari Collection, owner of luxury properties in Kenya, including the Giraffe Manor, Sasaab, Sala's Camp and Solio Lodge.

VVPR

Vivopower Subsidiary Tembo e-LV Secures Order For EV Conversion Kits From The Safari Collection

On April 28, 2025, Medicus Pharma Ltd. (the "Company") issued a press release announcing that the Company entered into a binding letter of intent, dated April 26, 2025 (the "Letter Agreement"), pursuant to which the Company has agreed to acquire all of the issued and outstanding shares of Antev Ltd. ("Antev") on a share exchange basis (the "Transaction"). Antev is a clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as first in market product for cardiovascular high-risk prostate cancer patients and patients with first acute urinary retention (AURr) episodes due to enlarged prostate. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.
Subject to certain assumptions, qualifications and conditions, the Company will negotiate and enter into a definitive agreement with Antev to acquire all issued and outstanding Antev shares, on a fully-diluted basis, in exchange for 2,666,600 common shares of the Company ("Consideration Shares"), representing approximately 19% of the issued and outstanding common shares of the Company as of the date of the Letter Agreement. In addition to resale restrictions prescribed under applicable securities laws, the Consideration Shares will be subject to a 9-month staggered lock-up release and an agreement granting certain voting rights in favor of Company management for a period of 36 months.
Upon the achievement of certain milestones related to potential future U.S. Food and Drug Administration ("FDA") Phase 2 and New Drug Administration approvals, Antev shareholders will be entitled to receive up to approximately US$65 million in additional contingent consideration.

MDCX

Medicus Pharma To Acquire Antev Ltd. For 19% Equity Stake, Or ~2.67M Shares, With Potential $65M In Milestone Payments For Prostate Drug Teverelix

Barclays analyst Brandon Oglenski maintains Saia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) with a Overweight and lowers the price target from $475 to $290.

SAIA

Barclays Maintains Overweight on Saia, Lowers Price Target to $290

Susquehanna analyst Charles Minervino maintains Schlumberger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) with a Positive and lowers the price target from $48 to $46.

Susquehanna Maintains Positive on Schlumberger, Lowers Price Target to $46

Avantor Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NYSE">AVTR</a>) reported in-line earnings for its <a href="https://www.benzinga.com/quote/AVTR/earnings">first quarter on Friday</a>.
The company posted adjusted EPS of 23 cents in line with consensus. The life science tools company reported sales of $1.58 billion, missing the consensus of $1.61 billion.
"While earnings and margin performance were in line with our plan, Lab Solutions revenue was impacted by reduced demand – particularly in our Education and Government end market – following recent policy changes," said Michael Stubblefield, president and CEO. "We are updating our full-year outlook to reflect ongoing funding and policy-related headwinds. While we are not satisfied with our current growth trajectory, we are implementing a comprehensive strategy to strengthen our Lab Solutions segment and are committed to moving with urgency to improve performance across the business."
On Friday, Avantor announced that Stubblefield intends to step down as director, president, and CEO. The Board has initiated a search process to identify the company's next CEO.
Avantor shares fell 16.6% to close at $12.93 on Friday.
These analysts made changes to their price targets on Avantor following earnings announcement.
<ul>
<li>Baird analyst Catherine Schulte maintained Avantor with an Outperform and lowered the price target from $21 to $17.</li>
<li>Morgan Stanley analyst Tejas Savant downgraded the stock from Overweight to Equal-Weight and lowered the price target from $25 to $15.</li>
<li>Barclays analyst Luke Sergott maintained Avantor with an Overweight rating and lowered the price target from $18 to $15.</li>
</ul>
Considering buying AVTR stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="562" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28092545/image-197-1024x562.png" alt="" class="wp-image-890981" style="width:600px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28092545/image-197-1024x562.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28092545/image-197-300x165.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28092545/image-197-768x421.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28092545/image-197.png 1136w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:
<ul>
<li> <a href="https://www.benzinga.com/25/04/45035424/top-3-health-care-stocks-that-may-rocket-higher-in-april">Top 3 Health Care Stocks That May Rocket Higher In April</a> </li>
</ul>
Photo via Shutterstock

Earnings

Markets

AVTR

Avantor Analysts Cut Their Forecasts After Q1 Results

Barclays analyst Lauren Lieberman maintains PepsiCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) with a Equal-Weight and lowers the price target from $143 to $135.

Barclays Maintains Equal-Weight on PepsiCo, Lowers Price Target to $135

Susquehanna analyst Joseph Stauff initiates coverage on TKO Group Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TKO#NYSE">TKO</a>) with a Positive rating and announces Price Target of $180.

Initiation

Susquehanna Initiates Coverage On TKO Group Holdings with Positive Rating, Announces Price Target of $180

Barclays analyst Seth Sigman maintains O'Reilly Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORLY#NASDAQ">ORLY</a>) with a Equal-Weight and raises the price target from $1250 to $1290.

ORLY

Barclays Maintains Equal-Weight on O'Reilly Automotive, Raises Price Target to $1290

Wedbush analyst Alicia Reese maintains Roku (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) with a Outperform and lowers the price target from $125 to $100.

ROKU

Wedbush Maintains Outperform on Roku, Lowers Price Target to $100

Barclays analyst Lauren Lieberman maintains Keurig Dr Pepper (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDP#NASDAQ">KDP</a>) with a Overweight and raises the price target from $37 to $38.

Barclays Maintains Overweight on Keurig Dr Pepper, Raises Price Target to $38

Q4 and 2024 Year-End Preliminary Unaudited Select Financial Results
<ul>
<li>Expected $72.3 million in cash &amp; cash equivalents and short-term investments as of December 31, 2024 (inclusive of a $18 million credit facility) compared to $85.6 million in cash &amp; cash equivalents and short-term investments as of December 31, 2023 (inclusive of a $15 million credit facility).</li>
<li>Expected U.S. Generally Accepted Accounting Principles (GAAP) net loss in 2024 of $111.8 million, or $7.01 loss per share, compared to $114.2 million, $11.32 loss per share, in 2023.</li>
<li>Expected fourth quarter 2024 GAAP net loss of $37.3 million, or $1.51 loss per share, compared to $38.5 million, or $2.56 loss per share, in Q3 2024 and $35.2 million, or $3.44 loss per share, in Q4 2023. &nbsp;</li>
</ul>
The preliminary results presented reflect the Company's estimates based solely upon information available, and the Company's final results could differ from these estimates due to the completion of the Company's financial closing procedures, final adjustments and other developments that may arise between now and the time such audited consolidated financial statements for the year ended December 31, 2024 are issued. The Company expects to release the fully audited 2024 financial statements on or before May 15, 2025.

Guidance

REE Automotive Provides 2024 Business Update; Reschedules The Release Date Of Its Q4 And FY24 Financial Results To Before The Market Opens On Thursday, May 15, 2025; Sees Q4 EPS $(1.51) Up From $(3.44) YoY

Barclays analyst David Anderson maintains Fiserv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>) with a Overweight and lowers the price target from $265 to $230.

Barclays Maintains Overweight on Fiserv, Lowers Price Target to $230

Wedbush analyst Robert Driscoll reiterates Revolution Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVMD#NASDAQ">RVMD</a>) with a Outperform and maintains $67 price target.

Reiteration

RVMD

Wedbush Reiterates Outperform on Revolution Medicines, Maintains $67 Price Target

Barclays analyst Michael Leithead maintains Element Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESI#NYSE">ESI</a>) with a Overweight and lowers the price target from $30 to $27.

Barclays Maintains Overweight on Element Solutions, Lowers Price Target to $27

Susquehanna analyst Joseph Stauff initiates coverage on Sphere Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPHR#NYSE">SPHR</a>) with a Positive rating and announces Price Target of $37.

SPHR

Susquehanna Initiates Coverage On Sphere Entertainment with Positive Rating, Announces Price Target of $37

A widespread power outage struck large parts of Spain and Portugal on Monday, disrupting daily life and causing travel chaos. Major cities including Madrid, Barcelona, Lisbon and Seville were affected, with reports of outages also emerging from parts <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/45034627/us-stock-futures-fall-as-markets-brace-for-earnings-from-microsoft-meta-apple-and-apple-this-week-earnings-estimates-dont-signal-a-recession-says-leading-analyst">of France and Andorra.&nbsp;</a>
The Details: The blackout shut down traffic lights, caused heavy congestion on roads, and halted operations at airports, train stations, and metro systems. 
Read Next: <a href="https://www.benzinga.com/25/04/45012792/trump-administration-to-resume-collections-on-student-loans-5-million-borrowers-in-default?utm_source=articleShare">Trump Administration To Resume Collections On Student Loans: 5 Million Borrowers In Default&nbsp;</a>
In Madrid, traffic reached a standstill after signals failed, prompting police to advise people to avoid unnecessary travel and drive cautiously. The Madrid Open tennis tournament was suspended and fans exited in the dark. At Lisbon's Humberto Delgado Airport, travelers waited in unlit terminals without air conditioning or running water, and shops only accepted cash.
Spain's national rail operator, Renfe, reported that the blackout stopped trains nationwide and led to canceled departures. Metro systems in Madrid, Barcelona, and Valencia were also evacuated or shut down.
Portugal's grid operator, Redes Energéticas Nacionais, confirmed that the entire Iberian Peninsula lost electrical supply and some regions in France were also impacted. E-Redes, which manages electricity distribution in Portugal, described the incident as part of a broader European problem and began restoring connections in phases.
Spanish grid operator Red Electrica said it was working closely with energy companies to restore power. It stressed that the cause was under investigation and that all resources were being dedicated to resolving the issue. 
Early reports suggest the outage may have originated from a failure in a high-voltage interconnector in France, possibly linked to a fire that damaged a crucial power line. This disconnected the Iberian Peninsula from the European grid and triggered cascading failures. However, investigations are ongoing, and officials have not ruled out other causes, including cyberattacks.
Power restoration is underway, but authorities warn it may take hours or longer. That&#8217;s due to the complexity of restarting the grid after such a large-scale blackout. 
Markets React: European markets traded higher on Monday, with all sectors in positive territory despite the power outages. The Vanguard FTSE European ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VGK#NYSE">VGK</a>) was up 0.08% in premarket trading in New York. 
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/global/25/04/44952117/apple-and-meta-fined-nearly-800-million-for-violating-european-unions-digital-markets-act?utm_source=articleShare">Apple And Meta Fined Nearly $800 Million For Violating European Union&#8217;s Digital Markets Act</a>&nbsp;</li>
</ul>
Photo: Shutterstock

Specialty ETFs

Eurozone

Global

ETFs

Massive Power Outages Hit Spain, Portugal Snarling Travel: Investigations Into Cause Underway

Barclays analyst Kannan Venkateshwar maintains Comcast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>) with a Equal-Weight and lowers the price target from $37 to $35.

CMCSA

Barclays Maintains Equal-Weight on Comcast, Lowers Price Target to $35

<a href="https://www.autonews.com/canada/anc-tesla-canada-pricing-increase-over-tariffs/">https://www.autonews.com/canada/anc-tesla-canada-pricing-increase-over-tariffs/</a>
<a href="https://autonews.com/tesla">Tesla</a> is raising prices in Canada and encouraging buyers to snap up cars that were imported before counter-tariffs were imposed on U.S.-made vehicles.

Macro Economic Events

Politics

Economics

General

'Tesla Hikes Canadian Prices And Pushes Its Pre-Tariff Inventory' - Automotive News

Press Releases

NUBURU Partners With COEPTIS NexGenAI Affiliates Network to Drive Innovation in AI and Robotics as Part of Its Transformation Plan

COEPTIS' NexGenAI Affiliates Partners with NUBURU Network to Drive Innovation in AI and Robotics as Part of its Transformation Plan

Biotech

Health Care

Coeptis Therapeutics Secures Worldwide Development and Commercialization Rights to Next-Generation GEAR™ Cell Therapy Platform Strengthening its High-Impact Precision Immuno-Oncology Pipeline

Coeptis Inc. (COEP) Expands Cancer Immunotherapy Portfolio with Exclusive GEAR Cell Therapy License

Coeptis (NASDAQ: COEP) Accelerates Growth with Strategic Partnerships and Innovation

NUBURU Announces Strategic Corporate Update Focused on Defense & Security, Advanced Technologies, and Growth Initiatives

COEPTIS Partners with NexGenAI Solutions Group to Launch New AI Co-Working Hub in India, Driving Global Innovation in Technology

COEPTIS (COEP) Expands Global Footprint with Strategic India Tech Hub

Coeptis Therapeutics, Inc. and Z Squared Inc. Announce Merger Agreement

COEP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Coeptis Therapeutics Holdings, Inc. Is Fair to Shareholders

ALNY

AMZN

AVGO

BURU

COEP

COIN

MARA

MSFT

PYPL

REGN

RIOT

RPRX

SMMT

VRTX

Allakos

Allarity Therapeutics, Inc. - Common stock

Allarity Therapeutics

ALX Oncology Holdings Inc. - Common Stock

ALX Oncology Holdings

BioAtla

Burning Rock Biotech Limited - American Depositary Shares

Burning Rock Biotech

Cardio Diagnostics Holdings Inc. - Common stock

Cardio Diagnostics Hldgs

CollPlant Biotechnologies Ltd. - Ordinary Shares

CollPlant Biotechnologies

Clene

Chemomab Therapeutics Ltd. - American Depositary Shares

Chemomab Therapeutics

CEL-SCI

Elevation Oncology

Generation Bio

CytoMed Therapeutics Limited - Ordinary Shares

CytoMed Therapeutics

Kala Bio

Kazia Therapeutics Limited - American Depositary Shares

Kazia Therapeutics

Longeveron

LakeShore Biopharma Co., Ltd - Ordinary Shares

LakeShore Biopharma

Lisata Therapeutics

Nanoviricides

OSR Holdings

Ovid Therapeutics

Passage Bio

Q32 Bio

Tenax Therapeutics

Tempest Therapeutics, Inc. - Common Stock

Comments

Coeptis Therapeutics

Coeptis Therapeutics (COEP) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル